Plus Therapeutics, Inc. provided revenue guidance for the fourth quarter of 2023 and calendar year of 2024. The company forecasts grant revenue of between $1 million to $1.5 million in fourth quarter of 2023 and between $6 million to $7 million for calendar year 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.27 USD | +6.57% | +31.98% | +29.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.71% | 9.71M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- PSTV Stock
- News Plus Therapeutics, Inc.
- Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024